Clinical Trials on Advanced HNSCC

Total 5917 results

National Cancer Institute (NCI)

Completed

Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery (S1310)

Hilar Cholangiocarcinoma | Advanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Liver Carcinoma | Recurrent Adult Liver Carcinoma | Recurrent Gallbladder Carcinoma | Stage IV Distal Bile Duct Cancer | Unresectable Extrahepatic Bile Duct Carcinoma | Stage II Gallbladder Cancer | Stage... and other conditions

United States
Daiichi Sankyo
Merck Sharp & Dohme LLC

Recruiting

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Melanoma | Cervical Cancer | Head and Neck Cancer | Gastric Cancer | Esophageal Cancer | Prostate Cancer | Bladder Cancer | Advanced Solid Tumor | Endometrial Cancer | Ovarian Carcinoma | Pancreatic Carcinoma

United States, Taiwan, Japan
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)

Recruiting

Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability

BRCA1 Gene Mutation | BRCA2 Gene Mutation | Recurrent Ovarian Carcinoma | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC... and other conditions

United States
Checkpoint Therapeutics, Inc.
Novotech (Australia) Pty Limited

Recruiting

Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers

Melanoma | Renal Cell Carcinoma | Head and Neck Cancer | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Non Hodgkin Lymphoma | Endometrial Cancer | Carcinoma, Small Cell | Urothelial Carcinoma | Classical Hodgkin Lymphoma | Merkel Cell Carcinoma | Cutaneous Squamous Cell Carcinoma | Malignant Mesothelioma, Advanced

Australia, New Zealand, Thailand, Ukraine, Spain, Russian Federation, France, Poland, South Africa
National Cancer Institute (NCI)

Completed

Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer

Multiple Endocrine Neoplasia Type 2A | Multiple Endocrine Neoplasia Type 2B | Recurrent Thyroid Gland Medullary Carcinoma | Hereditary Thyroid Gland Medullary Carcinoma | Locally Advanced Thyroid Gland Medullary Carcinoma | Sporadic Thyroid Gland Medullary Carcinoma | Stage III Thyroid Gland Medullary... and other conditions

United States
Eli Lilly and Company
Loxo Oncology, Inc.

Not yet recruiting

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (NEXUS-01)

Cervical Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Bladder Cancer | Triple Negative Breast Cancer | Advanced Solid Tumor | Metastatic Solid Tumor | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Renal Pelvis Cancer | Urinary Bladder Neoplasm | Recurrent...

United States
Incyte Corporation

Active, not recruiting

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors

Cervical Cancer | Nasopharyngeal Carcinoma | Mesothelioma | Advanced Solid Tumor | Small-cell Lung Cancer | Esophageal Squamous Cell Carcinoma | Urothelial Carcinoma | Merkel Cell Carcinoma | HepatoCellular Carcinoma | Cutaneous Squamous Cell Carcinoma | MSI-H/dMMR Tumors | PD-L1 Amplified Tumor (9p24.1)

France, United States, Japan, Belgium, Australia
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer

Metastatic Colorectal Adenocarcinoma | Advanced Colon Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage III Colon Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage IIIA Colon Cancer AJCC v8 | Stage IIIA Rectal Cancer... and other conditions

United States
Tempus AI
GlaxoSmithKline

Active, not recruiting

Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors (PAVO)

Melanoma | Head and Neck Cancer | Pancreatic Cancer | Esophageal Cancer | Solid Tumor | Metastatic Cancer | Endometrial Cancer | Urologic Cancer | Breast Tumor | Locally Advanced Solid Tumor | Lung Tumor | Colon Tumor, Malignant

United States
Nuvation Bio Inc.

Recruiting

NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

Breast Cancer | Pancreatic Cancer | Ovarian Cancer | Prostate Cancer | Breast Carcinoma | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | Advanced Solid Tumor | Cancer of the Ovary | Pancreas Cancer | Triple-negative Breast Cancer | Cancer of Pancreas | Pancreas Neoplasm | Prostate Neoplasm | Cancer... and other conditions

United States, Australia
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer

Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Unresectable Gastroesophageal Junction Adenocarcinoma | Locally Advanced Gastroesophageal Junction Adenocarcinoma | Postneoadjuvant Therapy Stage III... and other conditions

United States
Fate Therapeutics

Terminated

Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy

Melanoma | Lymphoma | Renal Cell Carcinoma | Cervical Cancer | Head and Neck Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | NSCLC | Advanced Solid Tumor | Small-cell Lung Cancer | HER2-positive Breast Cancer | Pancreas Cancer | Urothelial Carcinoma | Merkel Cell Carcinoma | Microsatellite Instability and other conditions

United States
Roswell Park Cancer Institute
National Comprehensive Cancer Network

Active, not recruiting

TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study

Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage III Colon Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage IIIA Colon Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Colon Cancer AJCC v8 | Stage IV Colon Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC... and other conditions

United States
Infinity Pharmaceuticals, Inc.

Active, not recruiting

A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549

Advanced Solid Tumors (Part A/B/C/D) | Non-small Cell Lung Cancer (Part E) | Melanoma (Part E) | Squamous Cell Cancer of the Head and Neck (Part E) | Triple Negative Breast Cancer (Part F) | Adrenocortical Carcinoma (Part G) | Mesothelioma (Part G) | High-circulating Myeloid-derived Suppressor Cells...

United States
National Cancer Institute (NCI)

Active, not recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Glioma | Hematopoietic and Lymphoid Cell Neoplasm | Melanoma | Lymphoma | Multiple Myeloma | Recurrent Ovarian Carcinoma | Breast Carcinoma | Recurrent Head and Neck Carcinoma | Recurrent Lung Carcinoma | Recurrent Skin Carcinoma | Gastric Carcinoma | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory... and other conditions

United States, Puerto Rico, Guam
GI Innovation, Inc.
Merck Sharp & Dohme LLC

Recruiting

GI-101 as a Single Agent or in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors

Melanoma | Sarcoma | Renal Cell Carcinoma | Cervical Cancer | Urinary Bladder Cancer | Vulvar Cancer | Advanced Solid Tumor | Metastatic Solid Tumor | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | Merkel Cell Carcinoma | Vaginal Cancer | Microsatellite Stable...

Korea, Republic of, United States
Fate Therapeutics

Completed

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Melanoma | Lymphoma | Renal Cell Carcinoma | Cervical Cancer | Head and Neck Cancer | Small Cell Lung Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | NSCLC | Advanced Solid Tumors | HER2-positive Breast Cancer | Pancreas Cancer | Urothelial Carcinoma | Merkel Cell Carcinoma | Microsatellite Instability and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

IACS-010759 in Advanced Cancers

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast... and other conditions

United States
Aminex Therapeutics, Inc.

Recruiting

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

Melanoma | Cervical Cancer | Cancer | Breast Cancer | Head and Neck Cancer | Gastric Cancer | Colorectal Cancer | Esophageal Cancer | Solid Tumor | Endometrial Cancer | Advanced Cancer | Diffuse Midline Glioma, H3 K27M-Mutant | Papillary Thyroid Cancer | Solid Carcinoma | Mesotheliomas Pleural | Glioma, Malignant | Ovary Cancer and other conditions

United States, Australia
Wake Forest University Health Sciences

Completed

Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC) (HOPE)

Unspecified Childhood Solid Tumor, Protocol Specific | Pseudomyxoma Peritonei | Stage IV Ovarian Epithelial Cancer | Stage IV Ovarian Germ Cell Tumor | Ovarian Sarcoma | Recurrent Ovarian Epithelial Cancer | Stage IV Colon Cancer | Recurrent Colon Cancer | Carcinoma of the Appendix | Ovarian Stromal Cancer and other conditions

United States
Cancer Research UK
UCB Biopharma SRL

Not yet recruiting

A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer

Uterine Cervical Neoplasms | Carcinoma, Non-Small-Cell Lung | Colorectal Neoplasms | Pancreatic Neoplasms | Esophageal Neoplasms | Ovarian Neoplasms | Squamous Cell Carcinoma of Head and Neck | Triple Negative Breast Neoplasms | Advanced Solid Tumours | Carcinoma, Renal Cell (Clear Cell Only) | Stomach Neoplasms...

United Kingdom
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Adenocarcinoma

Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Metastatic Gastroesophageal Junction Adenocarcinoma | Unresectable Gastroesophageal Junction Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma | Clinical Stage III Esophageal Adenocarcinoma AJCC v8 | Clinical Stage IV Esophageal Adenocarcinoma AJCC v8 and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Advanced Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Recurrent Grade 3a Follicular Lymphoma | Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Recurrent Mycosis Fungoides | Recurrent Primary Cutaneous... and other conditions

United States, Canada
Salubris Biotherapeutics Inc

Recruiting

Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer

Melanoma | Clear Cell Renal Cell Carcinoma | Cancer | Hepatocellular Carcinoma | Colorectal Cancer | Pancreatic Adenocarcinoma | Gastric Adenocarcinoma | Metastatic Cancer | Squamous Cell Carcinoma of Head and Neck | Triple Negative Breast Cancer | Advanced Solid Tumor | Epithelial Ovarian Cancer | Non-small Cell... and other conditions

Belgium, Spain
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Refractory Pancreatic Carcinoma | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Stage IV Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB... and other conditions

United States
National Cancer Institute (NCI)

Terminated

Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer

Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter | Regional Transitional Cell Cancer of the Renal Pelvis and Ureter | Stage III Bladder Cancer | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the Bladder | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage... and other conditions

United States
Emory University
National Cancer Institute (NCI)

Not yet recruiting

Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditions

United States
Volastra Therapeutics, Inc.

Recruiting

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

Gastric Adenocarcinoma | Uterine Carcinosarcoma | Triple Negative Breast Cancer | Advanced Solid Tumor | Head and Neck Squamous Cell Carcinoma | Esophageal Adenocarcinoma | Esophageal Squamous Cell Carcinoma | Transitional Cell Carcinoma of Bladder | Colorectal Adenocarcinoma | Gastroesophageal Junction... and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations

Recurrent Ovarian Carcinoma | Recurrent Head and Neck Carcinoma | Recurrent Renal Cell Carcinoma | Stage III Renal Cell Cancer | Endometrial Carcinoma | Stage III Bladder Cancer | Cervical Squamous Cell Carcinoma | Stage IV Breast Cancer | Malignant Uterine Neoplasm | Recurrent Bladder Carcinoma | Recurrent... and other conditions

United States
M.D. Anderson Cancer Center
Eisai Inc.

Withdrawn

Lenvatinib and Capecitabine in Patients With Advanced Malignancies

Advanced Cancer | Malignant Neoplasms of Female Genital Organs | Malignant Neoplasm of Breast | Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites | Malignant Neoplasms of Lip Oral Cavity and Pharynx | Malignant Neoplasms of Independent (Primary) Multiple Sites | Malignant Neoplasms... and other conditions
NKGen Biotech, Inc.

Withdrawn

Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers

Sarcoma | Cervical Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Metastatic Cancer | Bladder Cancer | Triple Negative Breast Cancer | Advanced Solid Tumor | HER2-positive Breast Cancer | Head and Neck Squamous Cell Carcinoma | EGF-R Positive Non-Small... and other conditions
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial

Ovarian Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Ovarian Serous Adenocarcinoma | Primary Peritoneal Serous Adenocarcinoma | Primary Peritoneal Clear... and other conditions

United States
National Cancer Institute (NCI)
AstraZeneca

Active, not recruiting

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

Metastatic Lung Non-Small Cell Carcinoma | Pancreatic Ductal Adenocarcinoma | Advanced Malignant Solid Neoplasm | Unresectable Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Stage III Pancreatic Cancer AJCC v6 and v7 | Stage IV Pancreatic Cancer AJCC v6 and v7 | Stage IIIA Lung Non-Small... and other conditions

United States, Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic

Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Metastatic Skin Squamous Cell Carcinoma | Unresectable Solid Neoplasm | Metastatic Kidney Medullary Carcinoma | Metastatic Penile Carcinoma | Small Cell Carcinoma | Metastatic Adrenal Gland Pheochromocytoma | Stage IV Penile Cancer... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)

Soft Tissue Sarcoma | Osteosarcoma | Ewing Sarcoma | Malignant Glioma | Ependymoma | Rhabdoid Tumor | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Rhabdomyosarcoma | Recurrent Malignant Solid Neoplasm | Recurrent Neuroblastoma | Refractory Neuroblastoma | Refractory Non-Hodgkin Lymphoma and other conditions

United States, Puerto Rico
Incyte Corporation

Active, not recruiting

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors

Cervical Cancer | Nasopharyngeal Carcinoma | Advanced Solid Tumors | Mesothelioma | Small-cell Lung Cancer | Esophageal Squamous Cell Carcinoma | Merkel Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Anal Carcinoma | Cutaneous Squamous Cell Carcinoma | MSI-H/dMMR Tumors | PD-L1 Amplified Tumor (9p24.1) | Urothelial... and other conditions

Finland, United States, United Kingdom, Belgium, Sweden, Denmark, Norway
Xencor, Inc.
ICON plc

Active, not recruiting

A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3)

Renal Cell Carcinoma | Nasopharyngeal Carcinoma | Small Cell Lung Cancer | Hepatocellular Carcinoma | Advanced Solid Tumors | Non-small Cell Lung Carcinoma | Squamous Cell Carcinoma of the Head and Neck | Cervical Carcinoma | Endometrial Carcinoma | Urothelial Carcinoma | Colorectal Carcinoma | Pancreatic Carcinoma and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)

Recurrent Childhood Ependymoma | Advanced Malignant Solid Neoplasm | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Medulloblastoma | Recurrent Neuroblastoma | Recurrent Non-Hodgkin... and other conditions

United States, Puerto Rico
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

Metastatic Renal Cell Carcinoma | Metastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Metastatic Melanoma | Fallopian Tube Carcinoma | Advanced Malignant Solid Neoplasm | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage III Renal... and other conditions

United States
Pamela Munster
Pfizer; Xynomic Pharmaceuticals, Inc.

Withdrawn

Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast... and other conditions
Xencor, Inc.
ICON Clinical Research

Completed

A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4)

Melanoma | Renal Cell Carcinoma | Nasopharyngeal Carcinoma | Small Cell Lung Carcinoma | Hepatocellular Carcinoma | Fallopian Tube Cancer | Non-small Cell Lung Carcinoma | Squamous Cell Carcinoma of the Head and Neck | Triple Negative Breast Cancer | Epithelial Ovarian Cancer | Intrahepatic Cholangiocarcinoma and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery

Hodgkin Lymphoma | Non-Hodgkin Lymphoma | Advanced Malignant Solid Neoplasm | Stage III Pancreatic Cancer AJCC v6 and v7 | Stage IV Pancreatic Cancer AJCC v6 and v7 | Metastatic Malignant Solid Neoplasm | Triple-Negative Breast Carcinoma | Unresectable Solid Neoplasm | Metastatic Malignant Neoplasm | Unresectable... and other conditions

United States
National Cancer Institute (NCI)
Children's Oncology Group

Recruiting

Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

Malignant Solid Neoplasm | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Malignant Solid Neoplasm | Recurrent... and other conditions

United States, Puerto Rico, Australia
National Cancer Institute (NCI)

Active, not recruiting

Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

Recurrent Childhood Medulloblastoma | Recurrent Childhood Ependymoma | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Glioma | Recurrent Malignant Solid Neoplasm | Recurrent Neuroblastoma and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)

Active, not recruiting

Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

Malignant Glioma | Recurrent Childhood Ependymoma | Rhabdoid Tumor | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Solid Neoplasm | Recurrent Medulloblastoma | Recurrent Neuroblastoma | Recurrent... and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)

Active, not recruiting

Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Histiocytic and Dendritic Cell Neoplasm | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Solid Neoplasm | Recurrent... and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)

Active, not recruiting

Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Malignant Solid Neoplasm | Recurrent Medulloblastoma | Recurrent... and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)

Active, not recruiting

Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)

Malignant Glioma | Rhabdoid Tumor | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Solid Neoplasm | Recurrent... and other conditions

United States, Puerto Rico
University of Chicago
National Cancer Institute (NCI)

Completed

Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies

Mucinous Adenocarcinoma of the Rectum | Signet Ring Adenocarcinoma of the Rectum | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Acinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Stage III Pancreatic Cancer | Stage IV Pancreatic... and other conditions

United States
Medicenna Therapeutics, Inc.
Merck Sharp & Dohme LLC

Recruiting

A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1)

Clear Cell Renal Cell Carcinoma | Cervical Cancer | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Fallopian Tube Cancer | Solid Tumor | Squamous Cell Carcinoma of Head and Neck | Bladder Cancer | Skin Cancer | Triple Negative Breast Cancer | Advanced Solid Tumor | Primary Peritoneal Cancer | Endometrial Carcinoma and other conditions

United States, Australia, Korea, Republic of, Canada

Clinical Trials on Advanced HNSCC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saudi Arabia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations